{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T06:58:01Z","timestamp":1780901881499,"version":"3.54.1"},"reference-count":215,"publisher":"Spandidos Publications","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Exp Ther Med"],"DOI":"10.3892\/etm.2026.13178","type":"journal-article","created":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T09:37:18Z","timestamp":1778233038000},"page":"1-17","source":"Crossref","is-referenced-by-count":0,"title":["Modulation of the tumor microenvironment by incretins and glucagon: Metabolic and immune mechanisms (Review)"],"prefix":"10.3892","volume":"32","author":[{"given":"Min","family":"Hu","sequence":"first","affiliation":[{"name":"Clinical Medical College, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan 610075, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang-Jun","family":"Jiang","sequence":"additional","affiliation":[{"name":"College of Health and Intelligent Engineering, Chengdu Medical College, Chengdu, Sichuan 610500, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Yi","sequence":"additional","affiliation":[{"name":"Department of Abdominal Oncology, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2249","published-online":{"date-parts":[[2026,5,8]]},"reference":[{"key":"key20260608090316_b1-ETM-32-1-13178","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"key20260608090316_b2-ETM-32-1-13178","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1002\/mco2.6","article-title":"Metabolism in tumor microenvironment: Implications for cancer immunotherapy","volume":"1","author":"Shi","year":"2020","journal-title":"MedComm (2020)"},{"key":"key20260608090316_b3-ETM-32-1-13178","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1158\/1055-9965.EPI-20-1245","article-title":"Type 2 diabetes and cancer: An umbrella review of observational and mendelian randomization studies","volume":"30","author":"Pearson-Stuttard","year":"2021","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"key20260608090316_b4-ETM-32-1-13178","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1007\/s12020-021-02884-x","article-title":"Obesity, metabolic syndrome, and cancer: Pathophysiological and therapeutic associations","volume":"74","author":"Mili","year":"2021","journal-title":"Endocrine"},{"key":"key20260608090316_b5-ETM-32-1-13178","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.2337\/db16-1477","article-title":"Diabetes, pancreatogenic diabetes, and pancreatic cancer","volume":"66","author":"Andersen","year":"2017","journal-title":"Diabetes"},{"issue":"847760","key":"key20260608090316_b6-ETM-32-1-13178","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.847760","article-title":"Identification of the shared gene signatures and biological mechanism in type 2 diabetes and pancreatic cancer","volume":"13","author":"Hu","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"327","key":"key20260608090316_b7-ETM-32-1-13178","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-020-01797-2","article-title":"Breast cancer risk factors and their effects on survival: A Mendelian randomisation study","volume":"18","author":"Escala-Garcia","year":"2020","journal-title":"BMC Med"},{"key":"key20260608090316_b8-ETM-32-1-13178","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1111\/jdi.12065","article-title":"Glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1: Incretin actions beyond the pancreas","volume":"4","author":"Seino","year":"2013","journal-title":"J Diabetes Investig"},{"issue":"101102","key":"key20260608090316_b9-ETM-32-1-13178","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2020.101102","article-title":"GLP-1 receptor agonists in the treatment of type 2 diabetes-state-of-the-art","volume":"46","author":"Nauck","year":"2021","journal-title":"Mol Metab"},{"key":"key20260608090316_b10-ETM-32-1-13178","doi-asserted-by":"publisher","first-page":"4360","DOI":"10.1111\/bph.15860","article-title":"A GLP-1\/glucagon (GCG)\/CCK2 receptors tri-agonist provides new therapy for obesity and diabetes","volume":"179","author":"Zhao","year":"2022","journal-title":"Br J Pharmacol"},{"key":"key20260608090316_b11-ETM-32-1-13178","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.cmet.2021.12.005","article-title":"Effects on weight loss and glycemic control with SAR441255, a potent unimolecular peptide GLP-1\/GIP\/GCG receptor triagonist","volume":"34","author":"Bossart","year":"2022","journal-title":"Cell Metab"},{"key":"key20260608090316_b12-ETM-32-1-13178","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1007\/s10549-011-1585-0","article-title":"The peptide-hormone glucagon-like peptide-1 activates cAMP and inhibits growth of breast cancer cells","volume":"132","author":"Ligumsky","year":"2012","journal-title":"Breast Cancer Res Treat"},{"issue":"120370","key":"key20260608090316_b13-ETM-32-1-13178","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2022.120370","article-title":"Glucagon-like peptide-1 receptor activation by liraglutide promotes breast cancer through NOX4\/ROS\/VEGF pathway","volume":"294","author":"Liu","year":"2022","journal-title":"Life Sci"},{"key":"key20260608090316_b14-ETM-32-1-13178","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.3892\/or.2015.4476","article-title":"Exenatide inhibits the growth of endometrial cancer Ishikawa xenografts in nude mice","volume":"35","author":"Zhang","year":"2016","journal-title":"Oncol Rep"},{"issue":"170749","key":"key20260608090316_b15-ETM-32-1-13178","doi-asserted-by":"publisher","DOI":"10.1016\/j.peptides.2022.170749","article-title":"GLP-1 and GIP receptor signaling in beta cells-a review of receptor interactions and co-stimulation","volume":"151","author":"Mayendraraj","year":"2022","journal-title":"Peptides"},{"key":"key20260608090316_b16-ETM-32-1-13178","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.1053\/j.gastro.2007.03.054","article-title":"Biology of incretins: GLP-1 and GIP","volume":"132","author":"Baggio","year":"2007","journal-title":"Gastroenterology"},{"key":"key20260608090316_b17-ETM-32-1-13178","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.physbeh.2017.02.039","article-title":"Signalling in the gut endocrine axis","volume":"176","author":"Gribble","year":"2017","journal-title":"Physiol Behav"},{"key":"key20260608090316_b18-ETM-32-1-13178","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1152\/physrev.00008.2017","article-title":"Pancreatic \u03b2-cell electrical activity and insulin secretion: Of mice and men","volume":"98","author":"Rorsman","year":"2018","journal-title":"Physiol Rev"},{"key":"key20260608090316_b19-ETM-32-1-13178","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1007\/BF00401145","article-title":"Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients","volume":"36","author":"Nauck","year":"1993","journal-title":"Diabetologia"},{"key":"key20260608090316_b20-ETM-32-1-13178","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1016\/j.cmet.2018.03.001","article-title":"Mechanisms of action and therapeutic application of glucagon-like peptide-1","volume":"27","author":"Drucker","year":"2018","journal-title":"Cell Metab"},{"key":"key20260608090316_b21-ETM-32-1-13178","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1172\/JCI99934","article-title":"Cardioprotective GLP-1 metabolite prevents ischemic cardiac injury by inhibiting mitochondrial trifunctional protein-\u03b1","volume":"130","author":"Siraj","year":"2020","journal-title":"J Clin Invest"},{"key":"key20260608090316_b22-ETM-32-1-13178","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/s41569-023-00849-3","article-title":"Glucagon-like peptide 1 receptor agonists: Cardiovascular benefits and mechanisms of action","volume":"20","author":"Ussher","year":"2023","journal-title":"Nat Rev Cardiol"},{"key":"key20260608090316_b23-ETM-32-1-13178","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1210\/endo.140.3.6550","article-title":"Pancreatic glucagon-like peptide-1 receptor couples to multiple G proteins and activates mitogen-activated protein kinase pathways in Chinese hamster ovary cells","volume":"140","author":"Montrose-Rafizadeh","year":"1999","journal-title":"Endocrinology"},{"key":"key20260608090316_b24-ETM-32-1-13178","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1038\/s41594-017-0011-7","article-title":"Structure and dynamics of GPCR signaling complexes","volume":"25","author":"Hilger","year":"2018","journal-title":"Nat Struct Mol Biol"},{"key":"key20260608090316_b25-ETM-32-1-13178","doi-asserted-by":"publisher","first-page":"5","DOI":"10.2337\/diabetes.53.1.5","article-title":"Epac: A new cAMP-binding protein in support of glucagon-like peptide-1 receptor-mediated signal transduction in the pancreatic beta-cell","volume":"53","author":"Holz","year":"2004","journal-title":"Diabetes"},{"key":"key20260608090316_b26-ETM-32-1-13178","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1042\/BST20150244","article-title":"The complexity of signalling mediated by the glucagon-like peptide-1 receptor","volume":"44","author":"Fletcher","year":"2016","journal-title":"Biochem Soc Trans"},{"key":"key20260608090316_b27-ETM-32-1-13178","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.parkreldis.2016.09.013","article-title":"Orthostatic hypotension in Parkinson's disease: Does it matter if asymptomatic?","volume":"33","author":"Merola","year":"2016","journal-title":"Parkinsonism Relat Disord"},{"key":"key20260608090316_b28-ETM-32-1-13178","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1021\/acs.biochem.4c00867","article-title":"Regulation of GLP-1 and glucagon receptor function by \u03b2-arrestins in metabolically important cell types","volume":"64","author":"Liu","year":"2025","journal-title":"Biochemistry"},{"issue":"113326","key":"key20260608090316_b29-ETM-32-1-13178","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2023.113326","article-title":"GLP-1 and GIP receptors signal through distinct \u03b2-arrestin 2-dependent pathways to regulate pancreatic \u03b2 cell function","volume":"42","author":"Za\u00efmia","year":"2023","journal-title":"Cell Rep"},{"key":"key20260608090316_b30-ETM-32-1-13178","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1038\/onc.2017.360","article-title":"mTORC2\/AKT\/HSF1\/HuR constitute a feed-forward loop regulating rictor expression and tumor growth in glioblastoma","volume":"37","author":"Holmes","year":"2018","journal-title":"Oncogene"},{"issue":"234","key":"key20260608090316_b31-ETM-32-1-13178","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-024-01931-z","article-title":"Glucagon-like peptide-1 receptor: Mechanisms and advances in therapy","volume":"9","author":"Zheng","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"key20260608090316_b32-ETM-32-1-13178","doi-asserted-by":"publisher","first-page":"906","DOI":"10.2337\/db18-1123","article-title":"Separate and combined glucometabolic effects of endogenous glucose-dependent insulinotropic polypeptide and glucagon-like peptide 1 in healthy individuals","volume":"68","author":"Gasbjerg","year":"2019","journal-title":"Diabetes"},{"key":"key20260608090316_b33-ETM-32-1-13178","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1111\/j.2040-1124.2012.00196.x","article-title":"Glucose-dependent insulinotropic polypeptide signaling in pancreatic \u03b2-cells and adipocytes","volume":"3","author":"Mcintosh","year":"2012","journal-title":"J Diabetes Investig"},{"key":"key20260608090316_b34-ETM-32-1-13178","doi-asserted-by":"publisher","first-page":"615","DOI":"10.2337\/diab.46.4.615","article-title":"Protein kinase A-dependent stimulation of exocytosis in mouse pancreatic beta-cells by glucose-dependent insulinotropic polypeptide","volume":"46","author":"Ding","year":"1997","journal-title":"Diabetes"},{"issue":"e230361","key":"key20260608090316_b35-ETM-32-1-13178","doi-asserted-by":"publisher","DOI":"10.1530\/JOE-23-0361","article-title":"The interplay of glucose-dependent insulinotropic polypeptide in adipose tissue","volume":"261","author":"Kagdi","year":"2024","journal-title":"J Endocrinol"},{"key":"key20260608090316_b36-ETM-32-1-13178","doi-asserted-by":"publisher","first-page":"37088","DOI":"10.1074\/jbc.M205055200","article-title":"Glucose-dependent insulinotropic polypeptide activates the Raf-Mek1\/2-ERK1\/2 module via a cyclic AMP\/cAMP-dependent protein kinase\/Rap1-mediated pathway","volume":"277","author":"Ehses","year":"2002","journal-title":"J Biol Chem"},{"key":"key20260608090316_b37-ETM-32-1-13178","doi-asserted-by":"publisher","first-page":"30372","DOI":"10.1074\/jbc.M109.060178","article-title":"Suppression of p38 MAPK and JNK via Akt-mediated inhibition of apoptosis signal-regulating kinase 1 constitutes a core component of the beta-cell pro-survival effects of glucose-dependent insulinotropic polypeptide","volume":"284","author":"Widenmaier","year":"2009","journal-title":"J Biol Chem"},{"key":"key20260608090316_b38-ETM-32-1-13178","doi-asserted-by":"publisher","first-page":"22297","DOI":"10.1074\/jbc.M500540200","article-title":"Glucose-dependent insulinotropic polypeptide (GIP) stimulation of pancreatic beta-cell survival is dependent upon phosphatidylinositol 3-kinase (PI3K)\/protein kinase B (PKB) signaling, inactivation of the forkhead transcription factor Foxo1, and down-regulation of bax expression","volume":"280","author":"Kim","year":"2005","journal-title":"J Biol Chem"},{"key":"key20260608090316_b39-ETM-32-1-13178","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1128\/MCB.00325-07","article-title":"Glucose-dependent insulinotropic polypeptide-mediated up-regulation of beta-cell antiapoptotic Bcl-2 gene expression is coordinated by cyclic AMP (cAMP) response element binding protein (CREB) and cAMP-responsive CREB coactivator 2","volume":"28","author":"Kim","year":"2008","journal-title":"Mol Cell Biol"},{"key":"key20260608090316_b40-ETM-32-1-13178","doi-asserted-by":"publisher","first-page":"2363","DOI":"10.2337\/db17-0480","article-title":"The Gluco- and liporegulatory and vasodilatory effects of glucose-dependent insulinotropic polypeptide (GIP) are abolished by an antagonist of the human GIP receptor","volume":"66","author":"Asmar","year":"2017","journal-title":"Diabetes"},{"key":"key20260608090316_b41-ETM-32-1-13178","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1038\/oby.2006.129","article-title":"Glucose-dependent insulinotropic polypeptide modulates adipocyte lipolysis and reesterification","volume":"14","author":"Getty-Kaushik","year":"2006","journal-title":"Obesity (Silver Spring)"},{"issue":"954","key":"key20260608090316_b42-ETM-32-1-13178","doi-asserted-by":"publisher","DOI":"10.1210\/endrev\/bnaf028","article-title":"Correction to: \u2018Glucose-dependent insulinotropic polypeptide in incretin physiology: Role in health and disease\u2019","volume":"46","year":"2025","journal-title":"Endocr Rev"},{"key":"key20260608090316_b43-ETM-32-1-13178","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1111\/jdi.13745","article-title":"Neuronal regulation of glucagon secretion and gluconeogenesis","volume":"13","author":"Thorens","year":"2022","journal-title":"J Diabetes Investig"},{"key":"key20260608090316_b44-ETM-32-1-13178","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1007\/s00125-016-3965-9","article-title":"Glucagon is the key factor in the development of diabetes","volume":"59","author":"Lee","year":"2016","journal-title":"Diabetologia"},{"key":"key20260608090316_b45-ETM-32-1-13178","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1016\/j.cmet.2022.10.001","article-title":". The past, present, and future physiology and pharmacology of glucagon","volume":"34","author":"Capozzi","year":"2022","journal-title":"Cell Metab"},{"key":"key20260608090316_b46-ETM-32-1-13178","doi-asserted-by":"publisher","first-page":"2998","DOI":"10.1016\/j.celrep.2019.02.035","article-title":"Ets1-mediated acetylation of FoxO1 Is critical for gluconeogenesis regulation during feed-fast cycles","volume":"26","author":"Li","year":"2019","journal-title":"Cell Rep"},{"key":"key20260608090316_b47-ETM-32-1-13178","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1016\/j.molcel.2012.09.030","article-title":"The deacetylase Sirt6 activates the acetyltransferase GCN5 and suppresses hepatic gluconeogenesis","volume":"48","author":"Dominy","year":"2012","journal-title":"Mol Cell"},{"key":"key20260608090316_b48-ETM-32-1-13178","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1007\/s10522-013-9478-8","article-title":"SIRT6, a protein with many faces","volume":"14","author":"Gertler","year":"2013","journal-title":"Biogerontology"},{"key":"key20260608090316_b49-ETM-32-1-13178","doi-asserted-by":"publisher","first-page":"E155","DOI":"10.1152\/ajpendo.90228.2008","article-title":"Insulin-like stimulation of cardiac fuel metabolism by physiological levels of glucagon: Involvement of PI3K but not cAMP","volume":"295","author":"Harney","year":"2008","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"key20260608090316_b50-ETM-32-1-13178","doi-asserted-by":"publisher","first-page":"C1552","DOI":"10.1152\/ajpcell.1998.274.6.C1552","article-title":"Glucagon-mediated Ca2+ signaling in BHK cells expressing cloned human glucagon receptors","volume":"274","author":"Hansen","year":"1998","journal-title":"Am J Physiol"},{"key":"key20260608090316_b51-ETM-32-1-13178","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/j.cmet.2012.03.002","article-title":"Calcium signaling through CaMKII regulates hepatic glucose production in fasting and obesity","volume":"15","author":"Ozcan","year":"2012","journal-title":"Cell Metab"},{"key":"key20260608090316_b52-ETM-32-1-13178","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/nature07349","article-title":"A fasting inducible switch modulates gluconeogenesis via activator\/coactivator exchange","volume":"456","author":"Liu","year":"2008","journal-title":"Nature"},{"key":"key20260608090316_b53-ETM-32-1-13178","doi-asserted-by":"publisher","first-page":"4326","DOI":"10.1074\/jbc.M113.540500","article-title":"Control of Foxo1 gene expression by co-activator P300","volume":"289","author":"Wondisford","year":"2014","journal-title":"J Biol Chem"},{"key":"key20260608090316_b54-ETM-32-1-13178","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1111\/dom.12958","article-title":"Treatment with LY2409021, a glucagon receptor antagonist, increases liver fat in patients with type 2 diabetes","volume":"19","author":"Guzman","year":"2017","journal-title":"Diabetes Obes Metab"},{"key":"key20260608090316_b55-ETM-32-1-13178","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1111\/j.1751-2980.2009.00416.x","article-title":"SIRT3 reduces lipid accumulation via AMPK activation in human hepatic cells","volume":"11","author":"Shi","year":"2010","journal-title":"J Dig Dis"},{"key":"key20260608090316_b56-ETM-32-1-13178","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1038\/s41586-020-2074-6","article-title":"Glucagon stimulates gluconeogenesis by INSP3R1-mediated hepatic lipolysis","volume":"579","author":"Perry","year":"2020","journal-title":"Nature"},{"key":"key20260608090316_b57-ETM-32-1-13178","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1152\/physrev.00025.2016","article-title":"The new biology and pharmacology of glucagon","volume":"97","author":"M\u00fcller","year":"2017","journal-title":"Physiol Rev"},{"key":"key20260608090316_b58-ETM-32-1-13178","doi-asserted-by":"publisher","first-page":"4121","DOI":"10.1128\/MCB.00665-15","article-title":"Lysine acetylation of CREBH regulates fasting-induced hepatic lipid metabolism","volume":"35","author":"Kim","year":"2015","journal-title":"Mol Cell Biol"},{"issue":"e15263","key":"key20260608090316_b59-ETM-32-1-13178","doi-asserted-by":"publisher","DOI":"10.14814\/phy2.15263","article-title":"Glucagon, cyclic AMP, and hepatic glucose mobilization: A half-century of uncertainty","volume":"10","author":"Rodgers","year":"2022","journal-title":"Physiol Rep"},{"issue":"32246","key":"key20260608090316_b60-ETM-32-1-13178","doi-asserted-by":"publisher","DOI":"10.1038\/srep32246","article-title":"Glucagon regulates hepatic lipid metabolism via cAMP and Insig-2 signaling: Implication for the pathogenesis of hypertriglyceridemia and hepatic steatosis","volume":"6","author":"Wang","year":"2016","journal-title":"Sci Rep"},{"key":"key20260608090316_b61-ETM-32-1-13178","doi-asserted-by":"publisher","first-page":"3501","DOI":"10.1111\/dom.15693","article-title":"Glucagon agonism in the treatment of metabolic diseases including type 2 diabetes mellitus and obesity","volume":"26","author":"Winther","year":"2024","journal-title":"Diabetes Obes Metab"},{"issue":"178290","key":"key20260608090316_b62-ETM-32-1-13178","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2025.178290","article-title":"Incretin signaling at the crossroads of metabolism, inflammation, and tumorigenesis: Implications for obesity patients","volume":"1007","author":"Wawrzak-Pienkowska","year":"2025","journal-title":"Eur J Pharmacol"},{"key":"key20260608090316_b63-ETM-32-1-13178","doi-asserted-by":"publisher","first-page":"C1822","DOI":"10.1152\/ajpcell.00245.2025","article-title":"GLP-1 receptor agonists in the context of cancer: The road ahead","volume":"328","author":"Miousse","year":"2025","journal-title":"Am J Physiol Cell Physiol"},{"issue":"120188","key":"key20260608090316_b64-ETM-32-1-13178","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2021.120188","article-title":"The current significance and prospects for the use of dual receptor agonism GLP-1\/Glucagon","volume":"288","author":"Spezani","year":"2022","journal-title":"Life Sci"},{"key":"key20260608090316_b65-ETM-32-1-13178","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1016\/j.ejmech.2017.07.046","article-title":"A novel glucagon-like peptide-1\/glucagon receptor dual agonist exhibits weight-lowering and diabetes-protective effects","volume":"138","author":"Zhou","year":"2017","journal-title":"Eur J Med Chem"},{"issue":"e13372","key":"key20260608090316_b66-ETM-32-1-13178","doi-asserted-by":"publisher","DOI":"10.1111\/obr.13372","article-title":"The incretin\/glucagon system as a target for pharmacotherapy of obesity","volume":"23","author":"Del Prato","year":"2022","journal-title":"Obes Rev"},{"key":"key20260608090316_b67-ETM-32-1-13178","doi-asserted-by":"publisher","first-page":"2086","DOI":"10.1038\/s42255-023-00938-0","article-title":"Cotadutide promotes glycogenolysis in people with overweight or obesity diagnosed with type 2 diabetes","volume":"5","author":"Parker","year":"2023","journal-title":"Nat Metab"},{"key":"key20260608090316_b68-ETM-32-1-13178","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1002\/oby.23108","article-title":"Obesity-associated myeloid immunosuppressive cells, key players in cancer risk and response to immunotherapy","volume":"29","author":"Sanchez-Pino","year":"2021","journal-title":"Obesity (Silver Spring)"},{"key":"key20260608090316_b69-ETM-32-1-13178","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.ygyno.2024.10.004","article-title":"Tirzepatide as an innovative treatment strategy in a pre-clinical model of obesity-driven endometrial cancer","volume":"191","author":"Kong","year":"2024","journal-title":"Gynecol Oncol"},{"issue":"10","key":"key20260608090316_b70-ETM-32-1-13178","doi-asserted-by":"publisher","DOI":"10.1038\/s44324-025-00054-5","article-title":"Incretin triple agonist retatrutide (LY3437943) alleviates obesity-associated cancer progression","volume":"3","author":"Marathe","year":"2025","journal-title":"NPJ Metab Health Dis"},{"issue":"e230404","key":"key20260608090316_b71-ETM-32-1-13178","doi-asserted-by":"publisher","DOI":"10.1530\/JOE-23-0404","article-title":"Gut hormone multi-agonists for the treatment of type 2 diabetes and obesity: Advances and challenges","volume":"262","author":"Huang","year":"2024","journal-title":"J Endocrinol"},{"issue":"e194743","key":"key20260608090316_b72-ETM-32-1-13178","doi-asserted-by":"publisher","DOI":"10.1172\/JCI194743","article-title":"GLP-1 receptor agonists and cancer: Current clinical evidence and translational opportunities for preclinical research","volume":"135","author":"Valencia-Rinc\u00f3n","year":"2025","journal-title":"J Clin Invest"},{"issue":"e2421305","key":"key20260608090316_b73-ETM-32-1-13178","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.21305","article-title":"Glucagon-like peptide 1 receptor agonists and 13 obesity-associated cancers in patients with type 2 diabetes","volume":"7","author":"Wang","year":"2024","journal-title":"JAMA Netw Open"},{"key":"key20260608090316_b74-ETM-32-1-13178","doi-asserted-by":"publisher","first-page":"216","DOI":"10.7326\/ANNALS-25-02237","article-title":"Risk for cancer with glucagon-like peptide-1 receptor agonists and dual agonists: A systematic review and meta-analysis","volume":"179","author":"Ko","year":"2026","journal-title":"Ann Intern Med"},{"key":"key20260608090316_b75-ETM-32-1-13178","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1001\/jamaoncol.2023.5573","article-title":"GLP-1 receptor agonists and colorectal cancer risk in drug-naive patients with type 2 diabetes, with and without overweight\/obesity","volume":"10","author":"Wang","year":"2024","journal-title":"JAMA Oncol"},{"key":"key20260608090316_b76-ETM-32-1-13178","doi-asserted-by":"publisher","first-page":"4454","DOI":"10.1111\/dom.16489","article-title":"GLP-1 receptor agonists and the risk for cancer: A meta-analysis of randomized controlled trials","volume":"27","author":"Silverii","year":"2025","journal-title":"Diabetes Obes Metab"},{"issue":"27","key":"key20260608090316_b77-ETM-32-1-13178","doi-asserted-by":"publisher","DOI":"10.3390\/ijms27010027","article-title":"The roles of incretin hormones GIP and GLP-1 in metabolic and cardiovascular health: A comprehensive review","volume":"27","author":"Yamanouchi","year":"2025","journal-title":"Int J Mol Sci"},{"issue":"1465881","key":"key20260608090316_b78-ETM-32-1-13178","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2024.1465881","article-title":"Glucagon-like peptide-1 receptor agonists in neoplastic diseases","volume":"15","author":"Ji","year":"2024","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"50","key":"key20260608090316_b79-ETM-32-1-13178","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-025-00765-3","article-title":"Glucagon-like peptide 1 receptor agonists and cancer risk: advancing precision medicine through mechanistic understanding and clinical evidence","volume":"13","author":"Lin","year":"2025","journal-title":"Biomark Res"},{"key":"key20260608090316_b80-ETM-32-1-13178","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.fertnstert.2022.04.027","article-title":"Liraglutide 3 mg on weight, body composition, and hormonal and metabolic parameters in women with obesity and polycystic ovary syndrome: A randomized placebo-controlled-phase 3 study","volume":"118","author":"Elkind-Hirsch","year":"2022","journal-title":"Fertil Steril"},{"issue":"41","key":"key20260608090316_b81-ETM-32-1-13178","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-023-01765-z","article-title":"Combination of exercise and GLP-1 receptor agonist treatment reduces severity of metabolic syndrome, abdominal obesity, and inflammation: A randomized controlled trial","volume":"22","author":"Sandsdal","year":"2023","journal-title":"Cardiovasc Diabetol"},{"issue":"10742484221146371","key":"key20260608090316_b82-ETM-32-1-13178","doi-asserted-by":"publisher","DOI":"10.1177\/10742484221146371","article-title":"Glucagon-like peptide-1 receptor agonists and dual glucose-dependent insulinotropic polypeptide\/glucagon-like peptide-1 receptor agonists in the treatment of obesity\/metabolic syndrome, prediabetes\/diabetes and non-alcoholic fatty liver disease-current evidence","volume":"27","author":"Muzurovi\u0107","year":"2022","journal-title":"J Cardiovasc Pharmacol Ther"},{"issue":"175896","key":"key20260608090316_b83-ETM-32-1-13178","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2023.175896","article-title":"Exendin-4 protects against high glucose-induced mitochondrial dysfunction and oxidative stress in SH-SY5Y neuroblastoma cells through GLP-1 receptor\/Epac\/Akt signaling","volume":"954","author":"Pandey","year":"2023","journal-title":"Eur J Pharmacol"},{"key":"key20260608090316_b84-ETM-32-1-13178","doi-asserted-by":"publisher","first-page":"10650","DOI":"10.18632\/oncotarget.24367","article-title":"Glucagon promotes colon cancer cell growth via regulating AMPK and MAPK pathways","volume":"9","author":"Yagi","year":"2018","journal-title":"Oncotarget"},{"key":"key20260608090316_b85-ETM-32-1-13178","doi-asserted-by":"publisher","first-page":"12","DOI":"10.23736\/S0026-4806.20.07123-2","article-title":"New development on hysteroscopy for endometrial cancer diagnosis: State of the art","volume":"112","author":"Carugno","year":"2021","journal-title":"Minerva Med"},{"issue":"92","key":"key20260608090316_b86-ETM-32-1-13178","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-024-01990-4","article-title":"Modulation of the tumor microenvironment and mechanism of immunotherapy-based drug resistance in breast cancer","volume":"23","author":"Kundu","year":"2024","journal-title":"Mol Cancer"},{"key":"key20260608090316_b87-ETM-32-1-13178","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.ccell.2023.02.016","article-title":"The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth","volume":"41","author":"De Visser","year":"2023","journal-title":"Cancer Cell"},{"key":"key20260608090316_b88-ETM-32-1-13178","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1038\/s43018-023-00672-2","article-title":"Presence of onco-fetal neighborhoods in hepatocellular carcinoma is associated with relapse and response to immunotherapy","volume":"5","author":"Li","year":"2024","journal-title":"Nat Cancer"},{"key":"key20260608090316_b89-ETM-32-1-13178","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.ccr.2012.02.014","article-title":"Metabolic reprogramming: A cancer hallmark even warburg did not anticipate","volume":"21","author":"Ward","year":"2012","journal-title":"Cancer Cell"},{"key":"key20260608090316_b90-ETM-32-1-13178","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1038\/nature13312","article-title":"Metabolism of stromal and immune cells in health and disease","volume":"511","author":"Ghesqui\u00e8re","year":"2014","journal-title":"Nature"},{"issue":"157","key":"key20260608090316_b91-ETM-32-1-13178","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-019-1089-9","article-title":"Role of hypoxia in cancer therapy by regulating the tumor microenvironment","volume":"18","author":"Jing","year":"2019","journal-title":"Mol Cancer"},{"key":"key20260608090316_b92-ETM-32-1-13178","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1038\/nature13490","article-title":"Functional polarization of tumour-associated macrophages by tumour-derived lactic acid","volume":"513","author":"Colegio","year":"2014","journal-title":"Nature"},{"key":"key20260608090316_b93-ETM-32-1-13178","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1038\/nri3175","article-title":"Coordinated regulation of myeloid cells by tumours","volume":"12","author":"Gabrilovich","year":"2012","journal-title":"Nat Rev Immunol"},{"key":"key20260608090316_b94-ETM-32-1-13178","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.cmet.2014.05.004","article-title":"The glucose transporter Glut1 is selectively essential for CD4 T cell activation and effector function","volume":"20","author":"Macintyre","year":"2014","journal-title":"Cell Metab"},{"key":"key20260608090316_b95-ETM-32-1-13178","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1016\/j.ccell.2023.02.009","article-title":"Functional states of myeloid cells in cancer","volume":"41","author":"van Vlerken-Ysla","year":"2023","journal-title":"Cancer Cell"},{"key":"key20260608090316_b96-ETM-32-1-13178","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1016\/j.ccell.2024.06.014","article-title":"Lymphatic-localized Treg-mregDC crosstalk limits antigen trafficking and restrains anti-tumor immunity","volume":"42","author":"You","year":"2024","journal-title":"Cancer Cell"},{"issue":"291","key":"key20260608090316_b97-ETM-32-1-13178","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-023-02845-4","article-title":"Amino acid metabolism reprogramming: Shedding new light on T cell anti-tumor immunity","volume":"42","author":"Zheng","year":"2023","journal-title":"J Exp Clin Cancer Res"},{"issue":"1352","key":"key20260608090316_b98-ETM-32-1-13178","doi-asserted-by":"publisher","DOI":"10.3390\/genes16111352","article-title":"GLP-1 receptor agonists in solid tumour therapy: Exploring their anticancer potential and underlying molecular pathways","volume":"16","author":"Lucente","year":"2025","journal-title":"Genes (Basel)"},{"issue":"1479","key":"key20260608090316_b99-ETM-32-1-13178","doi-asserted-by":"publisher","DOI":"10.3390\/biom14111479","article-title":"Anti-diabetic therapies and cancer: From bench to bedside","volume":"14","author":"Kounatidis","year":"2024","journal-title":"Biomolecules"},{"key":"key20260608090316_b100-ETM-32-1-13178","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1007\/s00018-017-2686-7","article-title":"CD4 and CD8 T lymphocyte interplay in controlling tumor growth","volume":"75","author":"Ostroumov","year":"2018","journal-title":"Cell Mol Life Sci"},{"key":"key20260608090316_b101-ETM-32-1-13178","doi-asserted-by":"publisher","first-page":"8509","DOI":"10.1002\/jcp.27782","article-title":"CD8+ cytotoxic T lymphocytes in cancer immunotherapy: A review","volume":"234","author":"Farhood","year":"2019","journal-title":"J Cell Physiol"},{"key":"key20260608090316_b102-ETM-32-1-13178","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.copbio.2021.02.003","article-title":"T cell metabolism in homeostasis and cancer immunity","volume":"68","author":"Wei","year":"2021","journal-title":"Curr Opin Biotechnol"},{"issue":"137","key":"key20260608090316_b103-ETM-32-1-13178","doi-asserted-by":"publisher","DOI":"10.1186\/s13578-025-01486-8","article-title":"Roles of glucagon-like peptide 1 receptor agonists in immune cell biology and autoimmune\/autoinflammatory diseases","volume":"15","author":"Deng","year":"2025","journal-title":"Cell Biosci"},{"key":"key20260608090316_b104-ETM-32-1-13178","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1016\/j.cmet.2024.05.001","article-title":"Glucagon-like peptide 1 receptor is a T cell-negative costimulatory molecule","volume":"36","author":"Ben Nasr","year":"2024","journal-title":"Cell Metab"},{"key":"key20260608090316_b105-ETM-32-1-13178","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.ajpath.2019.10.008","article-title":"Glucagon-like peptide-1 receptor agonism improves nephrotoxic serum nephritis by inhibiting T-cell proliferation","volume":"190","author":"Moschovaki Filippidou","year":"2020","journal-title":"Am J Pathol"},{"key":"key20260608090316_b106-ETM-32-1-13178","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.1016\/j.cmet.2022.08.003","article-title":"Divergent roles for the gut intraepithelial lymphocyte GLP-1R in control of metabolism, microbiota, and T cell-induced inflammation","volume":"34","author":"Wong","year":"2022","journal-title":"Cell Metab"},{"issue":"e194751","key":"key20260608090316_b107-ETM-32-1-13178","doi-asserted-by":"publisher","DOI":"10.1172\/JCI194751","article-title":"Antiinflammatory actions of glucagon-like peptide-1-based therapies beyond metabolic benefits","volume":"135","author":"Wong","year":"2025","journal-title":"J Clin Invest"},{"issue":"117668","key":"key20260608090316_b108-ETM-32-1-13178","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2024.117668","article-title":"Semaglutide decelerates the growth and progression of breast cancer by enhancing the acquired antitumor immunity","volume":"181","author":"Stanisavljevic","year":"2024","journal-title":"Biomed Pharmacother"},{"key":"key20260608090316_b109-ETM-32-1-13178","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.bbrc.2022.06.052","article-title":"Exenatide enhanced the antitumor efficacy on PD-1 blockade by the attenuation of neutrophil extracellular traps","volume":"619","author":"Chen","year":"2022","journal-title":"Biochem Biophys Res Commun"},{"key":"key20260608090316_b110-ETM-32-1-13178","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1002\/2211-5463.13499","article-title":"Liraglutide enhances the effect of checkpoint blockade in lung and liver cancers through the inhibition of neutrophil extracellular traps","volume":"14","author":"Chen","year":"2024","journal-title":"FEBS Open Bio"},{"issue":"e195484","key":"key20260608090316_b111-ETM-32-1-13178","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.195484","article-title":"Glucagon-like peptide-1 receptor agonism improves lung cancer outcomes and tumor growth control","volume":"10","author":"Pachimatla","year":"2025","journal-title":"JCI insight"},{"key":"key20260608090316_b112-ETM-32-1-13178","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.ccr.2009.06.017","article-title":"Polarization of tumor-associated neutrophil phenotype by TGF-beta: \u2018N1\u2019 versus \u2018N2\u2019 TAN","volume":"16","author":"Fridlender","year":"2009","journal-title":"Cancer Cell"},{"key":"key20260608090316_b113-ETM-32-1-13178","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1016\/j.immuni.2020.03.001","article-title":"CXCR1 and CXCR2 chemokine receptor agonists produced by tumors induce neutrophil extracellular traps that interfere with immune cytotoxicity","volume":"52","author":"Teijeira","year":"2020","journal-title":"Immunity"},{"issue":"785222","key":"key20260608090316_b114-ETM-32-1-13178","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.785222","article-title":"Neutrophil extracellular traps promote T cell exhaustion in the tumor microenvironment","volume":"12","author":"Kaltenmeier","year":"2021","journal-title":"Front Immunol"},{"key":"key20260608090316_b115-ETM-32-1-13178","doi-asserted-by":"publisher","first-page":"3403","DOI":"10.1111\/febs.17144","article-title":"A combined model of serum neutrophil extracellular traps, CD8+ T cells, and tumor proportion score provides better prediction of PD-1 inhibitor efficacy in patients with NSCLC","volume":"291","author":"Guo","year":"2024","journal-title":"FEBS J"},{"issue":"614","key":"key20260608090316_b116-ETM-32-1-13178","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-024-06976-0","article-title":"Natural Killer cells at the frontline in the fight against cancer","volume":"15","author":"Co\u00ebnon","year":"2024","journal-title":"Cell Death Dis"},{"issue":"302","key":"key20260608090316_b117-ETM-32-1-13178","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-024-02005-w","article-title":"Comprehensive snapshots of natural killer cells functions, signaling, molecular mechanisms and clinical utilization","volume":"9","author":"Chen","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"key20260608090316_b118-ETM-32-1-13178","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1002\/oby.23772","article-title":"Glucagon-like peptide-1 therapy in people with obesity restores natural killer cell metabolism and effector function","volume":"31","author":"De Barra","year":"2023","journal-title":"Obesity (Silver Spring)"},{"key":"key20260608090316_b119-ETM-32-1-13178","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1158\/2326-6066.CIR-17-0204","article-title":"NK cells control tumor-promoting function of neutrophils in mice","volume":"6","author":"Ogura","year":"2018","journal-title":"Cancer Immunol Res"},{"issue":"361","key":"key20260608090316_b120-ETM-32-1-13178","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-025-01140-z","article-title":"Mechanistic insights into IL-6-mediated NK cell dysfunction in NSCLC via the IRE1\u03b1-XBP1s-STAT3-UBE2S axis","volume":"9","author":"Wang","year":"2025","journal-title":"NPJ Precis Oncol"},{"issue":"100872","key":"key20260608090316_b121-ETM-32-1-13178","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2020.100872","article-title":"Liraglutide activates nature killer cell-mediated antitumor responses by inhibiting IL-6\/STAT3 signaling in hepatocellular carcinoma","volume":"14","author":"Lu","year":"2021","journal-title":"Transl Oncol"},{"issue":"110609","key":"key20260608090316_b122-ETM-32-1-13178","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2022.110609","article-title":"Metabolism drives macrophage heterogeneity in the tumor microenvironment","volume":"39","author":"Li","year":"2022","journal-title":"Cell Rep"},{"key":"key20260608090316_b123-ETM-32-1-13178","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1158\/0008-5472.CAN-13-1196","article-title":"Tumor hypoxia does not drive differentiation of tumor-associated macrophages but rather fine-tunes the M2-like macrophage population","volume":"74","author":"Laoui","year":"2014","journal-title":"Cancer Res"},{"issue":"80","key":"key20260608090316_b124-ETM-32-1-13178","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-023-01478-6","article-title":"Metabolism, metabolites, and macrophages in cancer","volume":"16","author":"Li","year":"2023","journal-title":"J Hematol Oncol"},{"key":"key20260608090316_b125-ETM-32-1-13178","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1038\/nrd.2018.169","article-title":"Targeting macrophages: Therapeutic approaches in cancer","volume":"17","author":"Cassetta","year":"2018","journal-title":"Nat Rev Drug Discov"},{"issue":"1295257","key":"key20260608090316_b126-ETM-32-1-13178","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1295257","article-title":"Tumor-associated macrophages: An effective player of the tumor microenvironment","volume":"14","author":"Basak","year":"2023","journal-title":"Front Immunol"},{"issue":"1567","key":"key20260608090316_b127-ETM-32-1-13178","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-05323-7","article-title":"Liraglutide, a glucagon-like peptide 1 receptor agonist, exerts analgesic, anti-inflammatory and anti-degradative actions in osteoarthritis","volume":"12","author":"Meurot","year":"2022","journal-title":"Sci Rep"},{"key":"key20260608090316_b128-ETM-32-1-13178","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1007\/s00125-017-4330-3","article-title":"The GLP-1 analogue lixisenatide decreases atherosclerosis in insulin-resistant mice by modulating macrophage phenotype","volume":"60","author":"Vinu\u00e9","year":"2017","journal-title":"Diabetologia"},{"key":"key20260608090316_b129-ETM-32-1-13178","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/j.bbrc.2012.07.086","article-title":"Glucagon-like peptide-1 (GLP-1) induces M2 polarization of human macrophages via STAT3 activation","volume":"425","author":"Shiraishi","year":"2012","journal-title":"Biochem Biophys Res Commun"},{"issue":"5568159","key":"key20260608090316_b130-ETM-32-1-13178","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/5568159","article-title":"Effect of GLP-1\/GLP-1R on the polarization of macrophages in the occurrence and development of atherosclerosis","volume":"2021","author":"Yang","year":"2021","journal-title":"Mediators Inflamm"},{"key":"key20260608090316_b131-ETM-32-1-13178","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1007\/s00125-013-3145-0","article-title":"Glucagon-like peptide 1 analogue therapy directly modulates innate immune-mediated inflammation in individuals with type 2 diabetes mellitus","volume":"57","author":"Hogan","year":"2014","journal-title":"Diabetologia"},{"issue":"31","key":"key20260608090316_b132-ETM-32-1-13178","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-024-00522-z","article-title":"Targeting M2-like tumor-associated macrophages is a potential therapeutic approach to overcome antitumor drug resistance","volume":"8","author":"Wang","year":"2024","journal-title":"NPJ Precis Oncol"},{"issue":"143","key":"key20260608090316_b133-ETM-32-1-13178","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-017-0626-3","article-title":"Liraglutide dictates macrophage phenotype in apolipoprotein E null mice during early atherosclerosis","volume":"16","author":"Bruen","year":"2017","journal-title":"Cardiovasc Diabetol"},{"key":"key20260608090316_b134-ETM-32-1-13178","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1016\/j.trecan.2023.05.003","article-title":"Interleukin-10 in cancer immunotherapy: From bench to bedside","volume":"9","author":"Salkeni","year":"2023","journal-title":"Trends Cancer"},{"issue":"554","key":"key20260608090316_b135-ETM-32-1-13178","doi-asserted-by":"publisher","DOI":"10.3390\/metabo14100554","article-title":"Liraglutide therapy in obese patients alters macrophage phenotype and decreases their tumor necrosis factor alpha release and oxidative stress markers-a pilot study","volume":"14","author":"Bu\u0142dak","year":"2024","journal-title":"Metabolites"},{"key":"key20260608090316_b136-ETM-32-1-13178","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1038\/s41416-024-02715-6","article-title":"Clinical landscape of macrophage-reprogramming cancer immunotherapies","volume":"131","author":"Rannikko","year":"2024","journal-title":"Br J Cancer"},{"key":"key20260608090316_b137-ETM-32-1-13178","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1038\/s41571-024-00859-1","article-title":"Dendritic cells as orchestrators of anticancer immunity and immunotherapy","volume":"21","author":"Heras-Murillo","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"issue":"1213629","key":"key20260608090316_b138-ETM-32-1-13178","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1213629","article-title":"Impaired function of dendritic cells within the tumor microenvironment","volume":"14","author":"Xiao","year":"2023","journal-title":"Front Immunol"},{"issue":"2","key":"key20260608090316_b139-ETM-32-1-13178","doi-asserted-by":"publisher","DOI":"10.3892\/ijmm.2025.5673","article-title":"Importance of B cells (review)","volume":"57","author":"Liu","year":"2026","journal-title":"Int J Mol Med"},{"key":"key20260608090316_b140-ETM-32-1-13178","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1038\/s41571-022-00619-z","article-title":"B cells and tertiary lymphoid structures as determinants of tumour immune contexture and clinical outcome","volume":"19","author":"Fridman","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"key20260608090316_b141-ETM-32-1-13178","doi-asserted-by":"publisher","first-page":"4790","DOI":"10.1016\/j.cell.2024.06.038","article-title":"Pan-cancer single-cell dissection reveals phenotypically distinct B cell subtypes","volume":"187","author":"Yang","year":"2024","journal-title":"Cell"},{"key":"key20260608090316_b142-ETM-32-1-13178","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.jss.2017.03.033","article-title":"B cells in tertiary lymphoid structures are associated with favorable prognosis in gastric cancer","volume":"215","author":"Sakimura","year":"2017","journal-title":"J Surg Res"},{"key":"key20260608090316_b143-ETM-32-1-13178","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.2337\/db05-1502","article-title":"Lymphocytic infiltration and immune activation in metallothionein promoter-exendin-4 (MT-Exendin) transgenic mice","volume":"55","author":"Baggio","year":"2006","journal-title":"Diabetes"},{"issue":"103","key":"key20260608090316_b144-ETM-32-1-13178","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-023-01498-2","article-title":"Lipid metabolic reprogramming in tumor microenvironment: From mechanisms to therapeutics","volume":"16","author":"Jin","year":"2023","journal-title":"J Hematol Oncol"},{"issue":"103363","key":"key20260608090316_b145-ETM-32-1-13178","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2025.103363","article-title":"The expanding role of GLP-1 receptor agonists: A narrative review of current evidence and future directions","volume":"86","author":"Moiz","year":"2025","journal-title":"EClinicalMedicine"},{"key":"key20260608090316_b146-ETM-32-1-13178","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1111\/jdi.13247","article-title":"Activation of overexpressed glucagon-like peptide-1 receptor attenuates prostate cancer growth by inhibiting cell cycle progression","volume":"11","author":"Shigeoka","year":"2020","journal-title":"J Diabetes Investig"},{"issue":"173102","key":"key20260608090316_b147-ETM-32-1-13178","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2020.173102","article-title":"Synergistic anti-tumor effects of Liraglutide, a glucagon-like peptide-1 receptor agonist, along with Docetaxel on LNCaP prostate cancer cell line","volume":"878","author":"Eftekhari","year":"2020","journal-title":"Eur J Pharmacol"},{"key":"key20260608090316_b148-ETM-32-1-13178","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1002\/pros.23687","article-title":"Exendin-4 enhances radiation response of prostate cancer","volume":"78","author":"He","year":"2018","journal-title":"Prostate"},{"key":"key20260608090316_b149-ETM-32-1-13178","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.ejphar.2017.05.015","article-title":"Liraglutide, a glucagon-like peptide-1 analog, induce autophagy and senescence in HepG2 cells","volume":"809","author":"Krause","year":"2017","journal-title":"Eur J Pharmacol"},{"issue":"1559325821995651","key":"key20260608090316_b150-ETM-32-1-13178","doi-asserted-by":"publisher","DOI":"10.1177\/1559325821995651","article-title":"Anti-proliferative activity of glucagon-like peptide-1 receptor agonist on obesity-associated breast cancer: The impact on modulating adipokines' expression in adipocytes and cancer cells","volume":"19","author":"Alanteet","year":"2021","journal-title":"Dose Response"},{"key":"key20260608090316_b151-ETM-32-1-13178","doi-asserted-by":"publisher","first-page":"E1431","DOI":"10.1152\/ajpendo.00017.2014","article-title":"Activation of glucagon-like peptide-1 receptor inhibits growth and promotes apoptosis of human pancreatic cancer cells in a cAMP-dependent manner","volume":"306","author":"Zhao","year":"2014","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"key20260608090316_b152-ETM-32-1-13178","doi-asserted-by":"publisher","first-page":"3362","DOI":"10.1210\/en.2011-1201","article-title":"Glucagon-like peptide-1 receptor activation inhibits growth and augments apoptosis in murine CT26 colon cancer cells","volume":"152","author":"Koehler","year":"2011","journal-title":"Endocrinology"},{"issue":"48","key":"key20260608090316_b153-ETM-32-1-13178","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01744-8","article-title":"Extracellular matrix remodeling in tumor progression and immune escape: From mechanisms to treatments","volume":"22","author":"Yuan","year":"2023","journal-title":"Mol Cancer"},{"issue":"2416","key":"key20260608090316_b154-ETM-32-1-13178","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-16199-4","article-title":"Targeting lysyl oxidase (LOX) overcomes chemotherapy resistance in triple negative breast cancer","volume":"11","author":"Saatci","year":"2020","journal-title":"Nat Commun"},{"issue":"1493","key":"key20260608090316_b155-ETM-32-1-13178","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25031493","article-title":"Semaglutide modulates extracellular matrix production of LX-2 cells via exosomes and improves metabolic dysfunction-associated steatotic liver disease (MASLD)","volume":"25","author":"Scavo","year":"2024","journal-title":"Int J Mol Sci"},{"issue":"20","key":"key20260608090316_b156-ETM-32-1-13178","doi-asserted-by":"publisher","DOI":"10.1007\/s00395-015-0476-7","article-title":"Exendin-4 protects against post-myocardial infarction remodelling via specific actions on inflammation and the extracellular matrix","volume":"110","author":"Robinson","year":"2015","journal-title":"Basic Res Cardiol"},{"key":"key20260608090316_b157-ETM-32-1-13178","doi-asserted-by":"publisher","first-page":"F458","DOI":"10.1152\/ajprenal.00128.2020","article-title":"Liraglutide suppresses production of extracellular matrix proteins and ameliorates renal injury of diabetic nephropathy by enhancing Wnt\/\u03b2-catenin signaling","volume":"319","author":"Huang","year":"2020","journal-title":"Am J Physiol Renal Physiol"},{"issue":"492","key":"key20260608090316_b158-ETM-32-1-13178","doi-asserted-by":"publisher","DOI":"10.21037\/atm-21-869","article-title":"Glucagon-like peptide-1 (GLP-1) improved diabetic lung fibrosis via AMPK and microRNA-27a (miR-27a)","volume":"9","author":"Liu","year":"2021","journal-title":"Ann Transl Med"},{"key":"key20260608090316_b159-ETM-32-1-13178","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1016\/j.apsb.2021.12.016","article-title":"Design of a highly potent GLP-1R and GCGR dual-agonist for recovering hepatic fibrosis","volume":"12","author":"Song","year":"2022","journal-title":"Acta Pharm Sin B"},{"issue":"113236","key":"key20260608090316_b160-ETM-32-1-13178","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2022.113236","article-title":"Application of glucagon-like peptide-1 receptor antagonists in fibrotic diseases","volume":"152","author":"Yang","year":"2022","journal-title":"Biomed Pharmacother"},{"issue":"121502","key":"key20260608090316_b161-ETM-32-1-13178","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2023.121502","article-title":"Treatment with semaglutide, a GLP-1 receptor agonist, improves extracellular matrix remodeling in the pancreatic islet of diet-induced obese mice","volume":"319","author":"Cardoso","year":"2023","journal-title":"Life Sci"},{"issue":"245","key":"key20260608090316_b162-ETM-32-1-13178","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-025-02311-x","article-title":"Mitochondrial metabolism and cancer therapeutic innovation","volume":"10","author":"Du","year":"2025","journal-title":"Signal Transduct Target Ther"},{"issue":"12993","key":"key20260608090316_b163-ETM-32-1-13178","doi-asserted-by":"publisher","DOI":"10.3390\/ijms232112993","article-title":"Mitochondrial role in oncogenesis and potential chemotherapeutic strategy of mitochondrial infusion in breast cancer","volume":"23","author":"Patel","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"189107","key":"key20260608090316_b164-ETM-32-1-13178","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2024.189107","article-title":"Decoding mitochondria's role in immunity and cancer therapy","volume":"1879","author":"Zhang","year":"2024","journal-title":"Biochim Biophys Acta Rev Cancer"},{"issue":"2699","key":"key20260608090316_b165-ETM-32-1-13178","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-30363-y","article-title":"Mitochondria preserve an autarkic one-carbon cycle to confer growth-independent cancer cell migration and metastasis","volume":"13","author":"Kiweler","year":"2022","journal-title":"Nat Commun"},{"key":"key20260608090316_b166-ETM-32-1-13178","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/j.bbrc.2014.03.004","article-title":"GLP-1 promotes mitochondrial metabolism in vascular smooth muscle cells by enhancing endoplasmic reticulum-mitochondria coupling","volume":"446","author":"Morales","year":"2014","journal-title":"Biochem Biophys Res Commun"},{"key":"key20260608090316_b167-ETM-32-1-13178","doi-asserted-by":"publisher","first-page":"1842","DOI":"10.1159\/000485820","article-title":"GLP-1 and ghrelin attenuate high glucose\/high lipid-induced apoptosis and senescence of human microvascular endothelial cells","volume":"44","author":"Liao","year":"2017","journal-title":"Cell Physiol Biochem"},{"issue":"109252","key":"key20260608090316_b168-ETM-32-1-13178","doi-asserted-by":"publisher","DOI":"10.1016\/j.cbi.2020.109252","article-title":"GLP-1 receptor agonist liraglutide protects cardiomyocytes from IL-1\u03b2-induced metabolic disturbance and mitochondrial dysfunction","volume":"332","author":"Zhang","year":"2020","journal-title":"Chem Biol Interact"},{"key":"key20260608090316_b169-ETM-32-1-13178","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.bbrc.2015.08.092","article-title":"GLP-1 contributes to increases in PGC-1\u03b1 expression by downregulating miR-23a to reduce apoptosis","volume":"466","author":"Wang","year":"2015","journal-title":"Biochem Biophys Res Commun"},{"issue":"111472","key":"key20260608090316_b170-ETM-32-1-13178","doi-asserted-by":"publisher","DOI":"10.1016\/j.mce.2021.111472","article-title":"Effect of GLP-1 receptor agonist, liraglutide, on muscle in spontaneously diabetic torii fatty rats","volume":"539","author":"Yamada","year":"2022","journal-title":"Mol Cell Endocrinol"},{"issue":"103129","key":"key20260608090316_b171-ETM-32-1-13178","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2024.103129","article-title":"Semaglutide attenuates doxorubicin-induced cardiotoxicity by ameliorating BNIP3-mediated mitochondrial dysfunction","volume":"72","author":"Li","year":"2024","journal-title":"Redox Biol"},{"issue":"e13677","key":"key20260608090316_b172-ETM-32-1-13178","doi-asserted-by":"publisher","DOI":"10.1002\/jcsm.13677","article-title":"The effects of glucagon-like peptide-1 receptor agonists on mitochondrial function within skeletal muscle: A systematic review","volume":"16","author":"Old","year":"2025","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"102849","key":"key20260608090316_b173-ETM-32-1-13178","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2023.102849","article-title":"Effects of GLP-1 receptor agonists on mitochondrial function, inflammatory markers and leukocyte-endothelium interactions in type 2 diabetes","volume":"66","author":"Luna-Marco","year":"2023","journal-title":"Redox Biol"},{"key":"key20260608090316_b174-ETM-32-1-13178","doi-asserted-by":"publisher","first-page":"540","DOI":"10.17179\/excli2019-1415","article-title":"Exenatide induces autophagy and prevents the cell regrowth in HepG2 cells","volume":"18","author":"Krause","year":"2019","journal-title":"EXCLI J"},{"key":"key20260608090316_b175-ETM-32-1-13178","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1053\/j.gastro.2024.04.029","article-title":"Association of GLP-1 receptor agonists and hepatocellular carcinoma incidence and hepatic decompensation in patients with type 2 diabetes","volume":"167","author":"Wang","year":"2024","journal-title":"Gastroenterology"},{"key":"key20260608090316_b176-ETM-32-1-13178","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1007\/s40264-025-01551-8","article-title":"Incretin-based drugs and the incidence of endometrial cancer among people with type 2 diabetes: Active comparator new-user design","volume":"48","author":"Rothman","year":"2025","journal-title":"Drug Saf"},{"key":"key20260608090316_b177-ETM-32-1-13178","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1111\/cob.12146","article-title":"Improvements in health-related quality of life with liraglutide 3.0 mg compared with placebo in weight management","volume":"6","author":"Kolotkin","year":"2016","journal-title":"Clin Obes"},{"key":"key20260608090316_b178-ETM-32-1-13178","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1111\/dom.14551","article-title":"Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss","volume":"24","author":"Wharton","year":"2022","journal-title":"Diabetes Obes Metab"},{"issue":"e2350408","key":"key20260608090316_b179-ETM-32-1-13178","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.50408","article-title":"Glucagon-like peptide-1 receptor agonists and pancreatic cancer risk in patients with type 2 diabetes","volume":"7","author":"Dankner","year":"2024","journal-title":"JAMA Netw Open"},{"key":"key20260608090316_b180-ETM-32-1-13178","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1111\/dom.12926","article-title":"Safety issues with glucagon-like peptide-1 receptor agonists (pancreatitis, pancreatic cancer and cholelithiasis): Data from randomized controlled trials","volume":"19","author":"Monami","year":"2017","journal-title":"Diabetes Obes Metab"},{"key":"key20260608090316_b181-ETM-32-1-13178","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1530\/JME-19-0186","article-title":"Activation of GLP-1 receptor enhances the chemosensitivity of pancreatic cancer cells","volume":"64","author":"Zhao","year":"2020","journal-title":"J Mol Endocrinol"},{"issue":"103242","key":"key20260608090316_b182-ETM-32-1-13178","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2021.103242","article-title":"Increased co-expression of PSMA2 and GLP-1 receptor in cervical cancer models in type 2 diabetes attenuated by exendin-4: A translational case-control study","volume":"65","author":"Mao","year":"2021","journal-title":"EBioMedicine"},{"issue":"793530","key":"key20260608090316_b183-ETM-32-1-13178","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.793530","article-title":"The GLP-1R agonist exendin-4 attenuates hyperglycemia-induced chemoresistance in human endometrial cancer cells through ROS-mediated mitochondrial pathway","volume":"11","author":"Zhang","year":"2021","journal-title":"Front Oncol"},{"issue":"e24604","key":"key20260608090316_b184-ETM-32-1-13178","doi-asserted-by":"publisher","DOI":"10.1002\/jcla.24604","article-title":"GLP1R inhibits the progression of endometrial carcinoma through activation of cAMP\/PKA pathway","volume":"36","author":"Li","year":"2022","journal-title":"J Clin Lab Anal"},{"key":"key20260608090316_b185-ETM-32-1-13178","doi-asserted-by":"publisher","first-page":"2417","DOI":"10.1210\/en.2014-1722","article-title":"Chronic toxicity and carcinogenicity studies of the long-acting GLP-1 receptor agonist dulaglutide in rodents","volume":"156","author":"Byrd","year":"2015","journal-title":"Endocrinology"},{"issue":"149882","key":"key20260608090316_b186-ETM-32-1-13178","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2024.149882","article-title":"Semaglutide alters gut microbiota and improves NAFLD in db\/db mice","volume":"710","author":"Mao","year":"2024","journal-title":"Biochem Biophys Res Commun"},{"key":"key20260608090316_b187-ETM-32-1-13178","doi-asserted-by":"publisher","first-page":"24293","DOI":"10.3390\/ijms141224293","article-title":"Effect of the GLP-1 analog exendin-4 and oxaliplatin on intrahepatic cholangiocarcinoma cell line and mouse model","volume":"14","author":"Chen","year":"2013","journal-title":"Int J Mol Sci"},{"key":"key20260608090316_b188-ETM-32-1-13178","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.regpep.2012.08.016","article-title":"Glucagon-like peptide-1 (GLP-1) receptor agonism or DPP-4 inhibition does not accelerate neoplasia in carcinogen treated mice","volume":"179","author":"Kissow","year":"2012","journal-title":"Regul Pept"},{"key":"key20260608090316_b189-ETM-32-1-13178","doi-asserted-by":"publisher","first-page":"4218","DOI":"10.1210\/en.2017-00461","article-title":"Exendin-4, a glucagonlike peptide-1 receptor agonist, attenuates breast cancer growth by inhibiting NF-\u03baB activation","volume":"158","author":"Iwaya","year":"2017","journal-title":"Endocrinology"},{"issue":"138","key":"key20260608090316_b190-ETM-32-1-13178","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-024-02390-w","article-title":"Glucagon-like peptide-1 analogs activate AMP kinase leading to reversal of the Warburg metabolic switch in breast cancer cells","volume":"41","author":"Ligumsky","year":"2024","journal-title":"Med Oncol"},{"key":"key20260608090316_b191-ETM-32-1-13178","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1001\/jamaoncol.2025.2681","article-title":"GLP-1 receptor agonists and cancer risk in adults with obesity","volume":"11","author":"Dai","year":"2025","journal-title":"JAMA Oncol"},{"issue":"e078225","key":"key20260608090316_b192-ETM-32-1-13178","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2023-078225","article-title":"Glucagon-like peptide 1 receptor agonist use and risk of thyroid cancer: Scandinavian cohort study","volume":"385","author":"Pasternak","year":"2024","journal-title":"BMJ"},{"key":"key20260608090316_b193-ETM-32-1-13178","doi-asserted-by":"publisher","first-page":"384","DOI":"10.2337\/dc22-1148","article-title":"GLP-1 receptor agonists and the risk of thyroid cancer","volume":"46","author":"Bezin","year":"2023","journal-title":"Diabetes Care"},{"issue":"4346","key":"key20260608090316_b194-ETM-32-1-13178","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25084346","article-title":"Assessment of thyroid carcinogenic risk and safety profile of GLP1-RA semaglutide (ozempic) therapy for diabetes mellitus and obesity: A systematic literature review","volume":"25","author":"Feier","year":"2024","journal-title":"Int J Mol Sci"},{"key":"key20260608090316_b195-ETM-32-1-13178","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","article-title":"A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis","volume":"384","author":"Newsome","year":"2021","journal-title":"N Engl J Med"},{"key":"key20260608090316_b196-ETM-32-1-13178","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1097\/EDE.0000000000000793","article-title":"Incretin-based drugs and the incidence of colorectal cancer in patients with type 2 diabetes","volume":"29","author":"Abrahami","year":"2018","journal-title":"Epidemiology"},{"issue":"107401","key":"key20260608090316_b197-ETM-32-1-13178","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2024.107401","article-title":"Glucagon-like peptide-1 receptor agonists and risk of gastrointestinal cancers: A systematic review and meta-analysis of randomized controlled trials","volume":"208","author":"Figlioli","year":"2024","journal-title":"Pharmacol Res"},{"key":"key20260608090316_b198-ETM-32-1-13178","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1210\/clinem\/dgaa891","article-title":"Do GLP-1 receptor agonists increase the risk of breast cancer? A systematic review and meta-analysis","volume":"106","author":"Piccoli","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"key20260608090316_b199-ETM-32-1-13178","doi-asserted-by":"publisher","first-page":"4688","DOI":"10.1097\/JS9.0000000000001514","article-title":"Association of glucagon-like peptide-1 receptor agonists with risk of cancers-evidence from a drug target Mendelian randomization and clinical trials","volume":"110","author":"Sun","year":"2024","journal-title":"Int J Surg"},{"key":"key20260608090316_b200-ETM-32-1-13178","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1093\/jnci\/djae260","article-title":"Glucagon-like peptide-1 receptor agonists and pancreatic cancer risk: Target trial emulation using real-world data","volume":"117","author":"Wang","year":"2025","journal-title":"J Natl Cancer Inst"},{"key":"key20260608090316_b201-ETM-32-1-13178","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1210\/en.2009-1272","article-title":"Glucagon-like peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation","volume":"151","author":"Bjerre Knudsen","year":"2010","journal-title":"Endocrinology"},{"key":"key20260608090316_b202-ETM-32-1-13178","doi-asserted-by":"publisher","first-page":"5621","DOI":"10.2147\/OTT.S150701","article-title":"Effects of insulin analogs and glucagon-like peptide-1 receptor agonists on proliferation and cellular energy metabolism in papillary thyroid cancer","volume":"10","author":"He","year":"2017","journal-title":"Onco Targets Ther"},{"key":"key20260608090316_b203-ETM-32-1-13178","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1111\/dme.13437","article-title":"No calcitonin change in a person taking dulaglutide diagnosed with pre-existing medullary thyroid cancer","volume":"35","author":"Sherman","year":"2018","journal-title":"Diabet Med"},{"key":"key20260608090316_b204-ETM-32-1-13178","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1080\/07435800.2021.1955255","article-title":"Differential risk of cancer associated with glucagon-like peptide-1 receptor agonists: Analysis of real-world databases","volume":"47","author":"Wang","year":"2022","journal-title":"Endocr Res"},{"key":"key20260608090316_b205-ETM-32-1-13178","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1089\/thy.2023.0530","article-title":"Glucagon-like peptide-1 receptor agonists and thyroid cancer: A narrative review","volume":"34","author":"Espinosa De Ycaza","year":"2024","journal-title":"Thyroid"},{"key":"key20260608090316_b206-ETM-32-1-13178","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.2337\/db05-1145","article-title":"Activation of glucagon-like peptide-1 receptor signaling does not modify the growth or apoptosis of human pancreatic cancer cells","volume":"55","author":"Koehler","year":"2006","journal-title":"Diabetes"},{"issue":"5722","key":"key20260608090316_b207-ETM-32-1-13178","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21165722","article-title":"Glucagon-like peptide-1 receptor agonist prevented the progression of hepatocellular carcinoma in a mouse model of nonalcoholic steatohepatitis","volume":"21","author":"Kojima","year":"2020","journal-title":"Int J Mol Sci"},{"key":"key20260608090316_b208-ETM-32-1-13178","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.mehy.2013.11.034","article-title":"Should GLP-1 receptor agonists be used with caution in high risk population for colorectal cancer?","volume":"82","author":"Sun","year":"2014","journal-title":"Med Hypotheses"},{"key":"key20260608090316_b209-ETM-32-1-13178","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1111\/apt.17925","article-title":"Impacts of glucagon-like peptide-1 receptor agonists on the risk of adverse liver outcomes in patients with metabolic dysfunction-associated steatotic liver disease cirrhosis and type 2 diabetes","volume":"59","author":"Elsaid","year":"2024","journal-title":"Aliment Pharmacol Ther"},{"issue":"901559","key":"key20260608090316_b210-ETM-32-1-13178","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.901559","article-title":"Effects of GLP-1 receptor agonists on biological behavior of colorectal cancer cells by regulating PI3K\/AKT\/mTOR signaling pathway","volume":"13","author":"Tong","year":"2022","journal-title":"Front Pharmacol"},{"issue":"594","key":"key20260608090316_b211-ETM-32-1-13178","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-023-11077-w","article-title":"High glucose promotes the progression of colorectal cancer by activating the BMP4 signaling and inhibited by glucagon-like peptide-1 receptor agonist","volume":"23","author":"Ma","year":"2023","journal-title":"BMC Cancer"},{"issue":"1387243","key":"key20260608090316_b212-ETM-32-1-13178","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1387243","article-title":"Comprehensively prognostic and immunological analyses of GLP-1 signaling-related genes in pan-cancer and validation in colorectal cancer","volume":"15","author":"Zhu","year":"2024","journal-title":"Front Pharmacol"},{"issue":"e2307271","key":"key20260608090316_b213-ETM-32-1-13178","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202307271","article-title":"Glucagon enhances chemotherapy efficacy by inhibition of tumor vessels in colorectal cancer","volume":"11","author":"Xu","year":"2024","journal-title":"Adv Sci (Weinh)"},{"issue":"598","key":"key20260608090316_b214-ETM-32-1-13178","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17040598","article-title":"Enhancing progestin therapy with a glucagon-like peptide 1 agonist for the conservative management of endometrial cancer","volume":"17","author":"Hagemann","year":"2025","journal-title":"Cancers (Basel)"},{"key":"key20260608090316_b215-ETM-32-1-13178","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.pharep.2015.10.008","article-title":"Exenatide (a GLP-1 agonist) expresses anti-inflammatory properties in cultured human monocytes\/macrophages in a protein kinase A and B\/Akt manner","volume":"68","author":"Bu\u0142dak","year":"2016","journal-title":"Pharmacol Rep"}],"container-title":["Experimental and Therapeutic Medicine"],"original-title":[],"deposited":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T06:03:25Z","timestamp":1780898605000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/etm.2026.13178"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,8]]},"references-count":215,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,5,8]]}},"URL":"https:\/\/doi.org\/10.3892\/etm.2026.13178","relation":{},"ISSN":["1792-0981","1792-1015"],"issn-type":[{"value":"1792-0981","type":"print"},{"value":"1792-1015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,8]]}}}